蒲地蓝消炎口服液联合支气管扩张药物治疗稳定期中重度COPD的临床观察

Clinical Observation of Pudilan Xiaoyan Oral Liquid Combined with Bronchial Dilatation Drugs in the Treatment of Moderate and Severe Stable Chronic Obstructive Pulmonary Disease

目的:观察蒲地蓝消炎口服液联合支气管扩张药物治疗稳定期中重度慢性阻塞性肺疾病(COPD)患者的临床疗效及安全性。方法:选取104例稳定期中重度COPD患者,按照入院时间随机分为治疗组(53例)和对照组(49例)。对照组患者给予布地奈德福莫特罗粉吸入剂与噻托溴铵干粉吸入剂进行治疗,治疗组患者在对照组基础上加用蒲地蓝消炎口服液,10 ml/次,3次/d。疗程均为12周。观察并比较两组患者肺功能指标、急性加重次数、呼吸困难评分(m MRC)、COPD评估测试(CAT)评分、COPD临床调查问卷(CCQ)评分等指标。结果:治疗12周后,治疗组患者深吸气量与治疗前及对照组比较均有明显改善,差异有统计学意义(P<0.05),但其第1秒用力呼气容积、第1秒用力呼气容积占用力肺活量比值与治疗前及对照组比较,差异无统计学意义(P>0.05);两组患者急性加重次数比较,差异无统计学意义(P>0.05);治疗组患者m MRC、CAT评分和CCQ总分与治疗前及对照组比较均有明显降低,差异有统计学意义(P<0.05)。两组患者均未见明显不良反应发生。结论:蒲地蓝消炎口服液联合支气管扩张药物吸入治疗稳定期中重度COPD的临床疗效优于单用干粉制剂吸入治疗,可明显改善患者肺功能,增加患者运动耐量,提高患者生存质量。

OBJECTIVE：To observe the clinical efficacy and safety of Pudilan xiaoyan oral liquid combined with bronchial dilatation drugs in the treatment of moderate to severe stable chronic obstructive pulmonary disease（COPD）. METHODS：According to admission time,102 patients with stable moderate to severe COPD were randomly divided into treatment group（n=53）and control group（n=49）. Control group received Budesonide and formoterol fumarate powder for inhalation and Tiotropium bromide powder for inhalation;based on control group,treatment group was additionally treated with Pudilan xiaoyan oral liquid,10 ml/time,3 times a day,for 12 weeks. The lung function index,number of acute COPD attack,modified medical research council（m MRC）,CAT and CCQ were performed and comparison in the two groups. RESULTS：After 12 weeks of treatment,the IC of treatment group was improved significantly,compared to before treatment and control group;there was statistical significance（P0.05）. There was no statistical significance in FEV1 and FEV1/ FVC% of treatment group after treatment,compared to before treatment and control group（P0.05）;there was no statistical significance in the number of acute COPD attack between 2 groups（P0.05）. m MRC,CAT score and CCQ total score of treatment group were improved significantly,compared to before treatment and control group;there was statistical significance（P0.05）. No obvious ADR was found in 2 groups. CONCLUSIONS：Pudilan xiaoyan oral liquid combined with bronchial dilatation drugs for inhalation is better than powder for inhalation in the treatment of moderate to serve stable COPD,can improve pulmonary function significantly,exercise tolerance and quality of life.